

Catalog Number: HZ-1336-GMP

## **Data Sheet**





Animal Component-Free

Human cell expressed

Tag-Free


**Endotoxin Free** 

## **Product Description**


Vascular endothelial growth factor C (VEGFc) is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family. VEGFC protein plays an essential role in angiogenesis (PMID: 9826710) and endothelial cell growth and migration (PMID: 18509061) and has a profound effect on the blood vasculature (PMID: 29484295). VEGFC can bind and activate signal transduction through both VEGFR-2 (flk1) and VEGFR-3 (flt4) receptors. The biosynthesis and maturation of VEGFC is a complex stepwise proteolytic process (PMID: 9233800), during which its properties and affinities for its interaction partners change. Only the fully processed form can bind and activate VEGFR-2 receptors (PMID: 21148085). Diseases associated with VEGFC include lymphatic malformations (PMID: 32513927) and Milroy-like primary lymphedema (PMID: 23410910).

Alternative Names	FLT4 ligand, FLT4-L, Vascular endothelial growth factor related protein (VRP), VRP, VEGFC, VRPFLT4 ligand DHM	
Accession Number	P49767	
Source	Human Embryonic Kidney cells (HEK293). HEK293-derived VEGF-C protein	
Species Reactivity	human	
Adventitious Virus	Master Cell Bank tested Negative for Adventitious Viruses	

Specifications					
Test	Method	Specification			
Activity	Dose-dependent production of luciferase in a Hek293T reporter cell line	2-16 ng/mL			
Molecular Mass	SDS-PAGE	18 and 28 kDa, homodimer, glycosylated			
Purity	SDS-PAGE	> 95%			
Endotoxin	LAL	<0.1 EU/µg			
Mycoplasma	PCR	Not Detected			



Recombinant human VEGF-C (HZ-1336) induces dosedependent luciferase production in a HEK293T reporter cell line.
Luciferase assay production was assessed by One-Step™ luciferase assay Kit.
HEK293T reporter cells were treated with increasing concentrations of recombinant VEGF-C for 18 hours. The EC50 was determined using a 4-parameter non-linear



Purity of recombinant human VEGF-C was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie

www.ptglab.com

Document #: FR-QA118-101 Rev 0 Data Sheet Version #: Proteintech Group, Inc.

5500 Pearl Street, Suite 400 Rosemont, IL 60612 t: 1-888-478-4522; f: 1-312-455-8408 Email: proteintech@ptglab.com

Preparation				
Shipping Temperature				
Formulation	50 mM Acetate pH 4.5 + 250 mM NaCl			
Reconstitution  Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein at 0.2 mg/mL in sterile 1x PBS processing containing 0.1% endotoxin-free recombinant serum albumin (HSA). Gently swirl or tap vial to mix				

	Product Form	Temperature Conditions	Storage Time (From Date of Receipt)	
	Lyophilized	-20°C to -80°C	Until Expiry Date	
Stability and Storage	Lyophilized	Room Temperature	2 weeks	
	Reconstituted as per CofA	-20°C to -80°C	6 months	
	Reconstituted as per CofA	4°C	1 week	
	Avoid repeated freeze-thaw cycles.			

## Proteintech GMP Quality Policy HumanKine® GMP Proteins

Invitro recombinant protein production can be prone to variability due to various reasons ranging from quality of raw materials to inconsistency in the process. Therefore, HumanKine®, a proteintech brand's GMP proteins are produced and tested under an ISO 13485 certified quality management system in a clean room facility. Proteintech manufactures the GMP HumanKine® products according to the applicable sections in the following documents: USP Chapter 1043 (Ancillary Materials for Cell, Gene, and Tissue-Engineered Products, USP Chapter 92 (Growth Factors and Cytokines Used in Cell Therapy Manufacturing), WHO TRS, No. 822, 1992 Annex 1 (Good Manufacturing Practices for Biological Products), Ph. Eur. General Chapter 5.2.12, and EudraLex – Volume 4 – Part IV (Guidelines on GMP specific to ATMPs). Proteintech strives to achieve the utmost quality GMP raw material ensuring all applicable guidelines are taken into consideration.

The QMS is built to provide our customers with consistent and pure product delivered by documented processes, qualified personnel, validated processes, qualified equipment, qualified vendors, and a stringent final product release process. Although the final product release process is important, Proteintech performs in-process QC steps after each major manufacturing stage. Production records and facilities may be available for an inspection by approved personnel.

Our GMP policy covers all the aspects of production; from raw materials, facility, equipment, and Instruments to training and personal hygiene of staff. It also guarantees that the process is explicit, validated and well documented for transparency and traceability.

www.ptglab.com

Document #: FR-QA118-101 Rev 0 Data Sheet Version #: Proteintech Group, Inc.

5500 Pearl Street, Suite 400 Rosemont, IL 60612 t: 1-888-478-4522; f: 1-312-455-8408 Email: proteintech@ptglab.com